{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:49:29Z","timestamp":1792622969950,"version":"4.5.0"},"reference-count":36,"publisher":"American Diabetes Association","issue":"3","license":[{"start":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T00:00:00Z","timestamp":1519084800000},"content-version":"vor","delay-in-days":77,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"name":"Veterans Affairs Cooperative Studies Program, Department of Veterans Affairs Office of Research and Development"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-HL110418"],"award-info":[{"award-number":["R01-HL110418"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-067690"],"award-info":[{"award-number":["R01-067690"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R01-094775"],"award-info":[{"award-number":["5R01-094775"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["4R44-DK101226-01A1"],"award-info":[{"award-number":["4R44-DK101226-01A1"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Heart Foundation Future Leader Fellowship","award":["100864"],"award-info":[{"award-number":["100864"]}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,3,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>The goal of this study was to determine whether plasma levels of advanced glycation end products (AGE) and oxidation products (OP) predict the incidence of cardiovascular disease (CVD) in type 2 diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Five specific AGE (methylglyoxal hydroimidazolone, carboxymethyl lysine, carboxyethyl lysine, 3-deoxyglucosone hydroimidazolone, and glyoxal hydroimidazolone) and two OP (2-aminoadipic acid and methionine sulfoxide [MetSO]) were measured at baseline in two intensive glucose-lowering studies: 1) a subcohort of the Veterans Affairs Diabetes Trial (VADT) (n = 445) and 2) a nested case-control subgroup from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study (n = 271).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Increased levels of several AGE and OP were associated with older age, decreased kidney function, previous CVD, and longer diabetes duration, but not with hemoglobin A1c. In the VADT, increased risk of incident CVD events (n = 107) was associated with lower MetSO after adjusting for age, race\/ethnicity, sex, prior CVD event, kidney function, treatment assignment, and diabetes duration (hazard ratio [HR] 0.53; 95% CI 0.28\u20130.99; P = 0.047). Individuals with both low MetSO and high 3-deoxyglucosone hydroimidazolone concentrations were at highest risk for CVD (HR 1.70; P = 0.01). In the ACCORD study, those with incident CVD events (n = 136) had lower MetSO (by 14%; P = 0.007) and higher glyoxal hydroimidazolone and carboxymethyl lysine (by 18% and 15%, respectively; P = 0.04 for both); however, only the difference in MetSO remained significant after adjustment for prior CVD event (P = 0.002).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Lower levels of MetSO and higher levels of select AGE are associated with increased incident CVD and may help account for the limited benefit of intensive glucose lowering in type 2 diabetes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc17-1740","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T01:25:41Z","timestamp":1512523541000},"page":"570-576","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":121,"title":["Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes"],"prefix":"10.2337","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct00032487","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00000620","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6671-6250","authenticated-orcid":false,"given":"Juraj","family":"Koska","sequence":"first","affiliation":[{"name":"Phoenix VA Health Care System, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aramesh","family":"Saremi","sequence":"additional","affiliation":[{"name":"Phoenix VA Health Care System, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Howell","sequence":"additional","affiliation":[{"name":"PreventAGE Healthcare, Lebanon, NH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon","family":"Bahn","sequence":"additional","affiliation":[{"name":"Hines VA Cooperative Studies Program Coordinating Center, Edward Hines Jr. VA Hospital, Hines, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8760-2511","authenticated-orcid":false,"given":"Barbora","family":"De Courten","sequence":"additional","affiliation":[{"name":"Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Ginsberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Beisswenger","sequence":"additional","affiliation":[{"name":"PreventAGE Healthcare, Lebanon, NH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Reaven","sequence":"additional","affiliation":[{"name":"Phoenix VA Health Care System, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the VADT Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2017,12,5]]},"reference":[{"key":"2022031301242530900_B1","first-page":"2215","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies [published correction appears in Lancet 2010;376:958]","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"2022031301242530900_B2","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031301242530900_B3","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Action to Control Cardiovascular Risk in Diabetes Study Group","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031301242530900_B4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"2022031301242530900_B5","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1161\/CIRCRESAHA.116.306923","article-title":"Molecular and cellular mechanisms of cardiovascular disorders in diabetes","volume":"118","author":"Shah","year":"2016","journal-title":"Circ Res"},{"key":"2022031301242530900_B6","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.110.223545","article-title":"Oxidative stress and diabetic complications","volume":"107","author":"Giacco","year":"2010","journal-title":"Circ Res"},{"key":"2022031301242530900_B7","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The pathobiology of diabetic complications: a unifying mechanism","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"key":"2022031301242530900_B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/diabetes.48.1.1","article-title":"Role of oxidative stress in diabetic complications: a new perspective on an old paradigm","volume":"48","author":"Baynes","year":"1999","journal-title":"Diabetes"},{"key":"2022031301242530900_B9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2337\/db09-0801","article-title":"Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands","volume":"59","author":"Yao","year":"2010","journal-title":"Diabetes"},{"key":"2022031301242530900_B10","doi-asserted-by":"crossref","first-page":"E1369","DOI":"10.1210\/jc.2013-1068","article-title":"Plasma levels of advanced glycation endproducts N\u03b5-(carboxymethyl)lysine, N\u03b5-(carboxyethyl)lysine, and pentosidine are not independently associated with cardiovascular disease in individuals with or without type 2 diabetes: the Hoorn and CODAM studies","volume":"98","author":"Hanssen","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031301242530900_B11","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2337\/diacare.22.9.1543","article-title":"Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease","volume":"22","author":"Kilhovd","year":"1999","journal-title":"Diabetes Care"},{"key":"2022031301242530900_B12","doi-asserted-by":"crossref","first-page":"670","DOI":"10.2337\/dc06-1508","article-title":"Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease","volume":"30","author":"Lapolla","year":"2007","journal-title":"Diabetes Care"},{"key":"2022031301242530900_B13","first-page":"201","article-title":"Serum N-epsilon-(carboxymethyl)lysine is elevated in nondiabetic coronary heart disease patients","volume-title":"J Basic Clin Physiol Pharmacol","author":"Dworacka","year":"2002"},{"key":"2022031301242530900_B14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.metabol.2004.09.014","article-title":"High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes","volume":"54","author":"Yoshida","year":"2005","journal-title":"Metabolism"},{"key":"2022031301242530900_B15","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/BF03325227","article-title":"Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women","volume":"21","author":"Semba","year":"2009","journal-title":"Aging Clin Exp Res"},{"key":"2022031301242530900_B16","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/j.1532-5415.2009.02438.x","article-title":"Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults","volume":"57","author":"Semba","year":"2009","journal-title":"J Am Geriatr Soc"},{"key":"2022031301242530900_B17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.atherosclerosis.2014.04.013","article-title":"Advanced glycation\/glycoxidation endproduct carboxymethyl-lysine and incidence of coronary heart disease and stroke in older adults","volume":"235","author":"Kizer","year":"2014","journal-title":"Atherosclerosis"},{"key":"2022031301242530900_B18","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00125-007-0687-z","article-title":"Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study","volume":"50","author":"Kilhovd","year":"2007","journal-title":"Diabetologia"},{"key":"2022031301242530900_B19","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1161\/01.ATV.0000158380.44231.fe","article-title":"High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study","volume":"25","author":"Kilhovd","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022031301242530900_B20","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2337\/dc16-1875","article-title":"Advanced glycation end products, oxidation products, and the extent of atherosclerosis during the VA Diabetes Trial and Follow-up Study","volume":"40","author":"Saremi","year":"2017","journal-title":"Diabetes Care"},{"key":"2022031301242530900_B21","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"2022031301242530900_B22","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.atherosclerosis.2008.07.031","article-title":"Association between IL-6 and the extent of coronary atherosclerosis in the Veterans Affairs Diabetes Trial (VADT)","volume":"203","author":"Saremi","year":"2009","journal-title":"Atherosclerosis"},{"key":"2022031301242530900_B23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00726-013-1533-x","article-title":"Detection of diabetic nephropathy from advanced glycation endproducts (AGEs) differs in plasma and urine, and is dependent on the method of preparation","volume":"46","author":"Beisswenger","year":"2014","journal-title":"Amino Acids"},{"key":"2022031301242530900_B24","first-page":"A117","article-title":"Oxidative and advanced glycation end products predict cardiovascular disease in type 1 diabetes","volume":"66(Suppl. 1)","author":"Beisswenger","year":"2017","journal-title":"Diabetes"},{"key":"2022031301242530900_B25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0047-6374(98)00152-3","article-title":"Methionine residues may protect proteins from critical oxidative damage","volume":"107","author":"Levine","year":"1999","journal-title":"Mech Ageing Dev"},{"key":"2022031301242530900_B26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/15216540051081056","article-title":"Oxidation of methionine in proteins: roles in antioxidant defense and cellular regulation","volume":"50","author":"Levine","year":"2000","journal-title":"IUBMB Life"},{"key":"2022031301242530900_B27","first-page":"121","article-title":"Redox modulation of cellular signaling and metabolism through reversible oxidation of methionine sensors in calcium regulatory proteins","volume-title":"Biochim Biophys Acta","author":"Bigelow","year":"2005"},{"key":"2022031301242530900_B28","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/eurheartj\/eht402","article-title":"Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype","volume":"35","author":"Hanssen","year":"2014","journal-title":"Eur Heart J"},{"key":"2022031301242530900_B29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2337\/db13-1864","article-title":"Plasma advanced glycation end products are associated with incident cardiovascular events in individuals with type 2 diabetes: a case-cohort study with a median follow-up of 10 years (EPIC-NL)","volume":"64","author":"Hanssen","year":"2015","journal-title":"Diabetes"},{"key":"2022031301242530900_B30","doi-asserted-by":"crossref","first-page":"e0128293","DOI":"10.1371\/journal.pone.0128293","article-title":"Association between advanced glycation end products and impaired fasting glucose: results from the SALIA Study","volume":"10","author":"Teichert","year":"2015","journal-title":"PLoS One"},{"key":"2022031301242530900_B31","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1042\/bj20030763","article-title":"Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry","volume":"375","author":"Thornalley","year":"2003","journal-title":"Biochem J"},{"key":"2022031301242530900_B32","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/ndt\/gfg619","article-title":"Increased levels of N(epsilon)-(carboxymethyl)lysine and N(epsilon)-(carboxyethyl)lysine in type 1 diabetic patients with impaired renal function: correlation with markers of endothelial dysfunction","volume":"19","author":"Lieuw-A-Fa","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"2022031301242530900_B33","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.2337\/db16-0310","article-title":"Advanced glycation end products predict loss of renal function and correlate with lesions of diabetic kidney disease in American Indians with type 2 diabetes","volume":"65","author":"Saulnier","year":"2016","journal-title":"Diabetes"},{"key":"2022031301242530900_B34","doi-asserted-by":"crossref","first-page":"6474","DOI":"10.1073\/pnas.94.12.6474","article-title":"Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy","volume":"94","author":"Koschinsky","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022031301242530900_B35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000046699","article-title":"Metabolic transit and in vivo effects of melanoidins and precursor compounds deriving from the Maillard reaction","volume":"45","author":"Faist","year":"2001","journal-title":"Ann Nutr Metab"},{"key":"2022031301242530900_B36","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.2337\/diacare.28.10.2465","article-title":"Glycated and oxidized protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes","volume":"28","author":"Ahmed","year":"2005","journal-title":"Diabetes Care"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc17-1740","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/41\/3\/570\/552776\/dc171740.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/41\/3\/570\/552776\/dc171740.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T05:14:20Z","timestamp":1647148460000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/41\/3\/570\/36655\/Advanced-Glycation-End-Products-Oxidation-Products"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,5]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,12,5]]},"published-print":{"date-parts":[[2018,3,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc17-1740","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,5]]}}}